Moderna is using broad brush strokes in its bid for authorization of a second booster dose, compared to Pfizer/BioNTech's narrower request. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
